PRL3-zumab, a first-in-class humanized antibody for cancer therapy

Novel, tumor-specific drugs are urgently needed for a breakthrough in cancer therapy. Herein, we generated a first-in-class humanized antibody (PRL3-zumab) against PRL-3, an intracellular tumor-associated phosphatase upregulated in multiple human cancers, for unconventional cancer immunotherapies. W...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCI Insight
Autors principals: Thura, Min, Al-Aidaroos, Abdul Qader Omer, Yong, Wei Peng, Kono, Koji, Gupta, Abhishek, Lin, You Bin, Mimura, Kousaku, Thiery, Jean Paul, Goh, Boon Cher, Tan, Patrick, Soo, Ross, Hong, Cheng William, Wang, Lingzhi, Lin, Suling Joyce, Chen, Elya, Rha, Sun Young, Chung, Hyun Cheol, Li, Jie, Nandi, Sayantani, Yuen, Hiu Fung, Zhang, Shu-Dong, Guan, Yeoh Khay, So, Jimmy, Zeng, Qi
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033845/
https://ncbi.nlm.nih.gov/pubmed/27699276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.87607
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars